ISPC
iSpecimen Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.54
+0.00%Sep 4, 2026, 20:53 UTC
iSpecimen Inc. agreed to acquire certain artificial intelligence software, models, source code, data rights, and intellectual property from Foldlab AI Ltd. for an aggregate purchase price of $4,500,000, consisting of $2,000,000 in cash and $2,500,000 in shares of common stock, subject to stockholder and Nasdaq approval.
Aug 31, 2026, 21:30 UTC
Katharyn Field departed as Chief Executive Officer of iSpecimen Inc., effective 2026-08-26, and was succeeded by Shahin Behroyan.
Aug 20, 2026, 20:05 UTC
iSpecimen completed a large-scale international cancer research order, shipping hundreds of cancer blood specimens within three weeks of receiving the purchase order.
Source:Aug 7, 2026, 19:45 UTC
E.F. Hutton & Co. acted as exclusive placement agent for iSpecimen's $5.0 million public offering, marking the third capital markets engagement between the two since December 2025.
Jun 1, 2026, 00:00 UTC
iSpecimen Inc. received a notice from Nasdaq on May 29, 2026, stating that the company no longer complies with the minimum stockholders' equity requirement under Listing Rule 5550(b)(1).